Disulfiram as a Modulator of Amyloid Precursor Protein-processing

Quantitative Analysis of the Expression of Dementia-relevant Genes by Intake of the Drug Disulfiram

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03212599

Acronym

DIMAP

Enrollment

Registered

2017-07-11

Start date

2013-05-31

Completion date

2017-07-31

Last updated

2017-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Addiction

Keywords

APP-processing, Disulfiram, ADAM10, Alzheimer's disease, blood

Brief summary

A causal therapeutic approach for treatment of Alzheimer's disease has not been established so far. The protein ADAM10 represents a promising target for an A-beta peptide preventing strategy. Treatment of human neuronal cells with Disulfiram, a drug which is used in clinical routine for recrudescence prevention of alcohol dependency, revealed an increased expression of ADAM10. This finding indicates a neuroprotective potential of Disulfiram. The investigators' research purpose aims at the verification of the results obtained in cell culture experiments in the human organism. Therefore, include alcohol addicted patients were included, which take the drug Disulfiram for recrudescence prevention, in our study. Patients are recruited from the patient-collective of the University Medical Center Mainz and the Central Institute for Mental Health Mannheim. Blood samples (max. 5 ml) are taken from the participants before the intake of Disulfiram and about two weeks after treatment. Demographic data are collected (such as age or onset of addiction). Gene expression is analyzed via reverse transcription polymerase chain reaction(RT-PCR) from blood cell-derived messenger ribonucleic acid (mRNA).

Interventions

DRUGDisulfiram

alcohol addicted patients receive an oral Disulfiram application as recrudescence prevention after successful detoxication

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

ambulant or stationary patients, which receive Disulfiram for recrudescence prevention

Exclusion criteria

Diagnosed Alzheimer's dementia Previous Disulfiram treatment less than four weeks before baseline blood collection

Design outcomes

Primary

Measure	Time frame	Description
expression of ADAM10	August 2016	expression of ADAM10 in the collected blood samples measured by quantitation of the mRNA amount using RealTime-RT-PCR.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026